PI Industries Annual Report Update - CSM Segment Going From Strength To Strength: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
PI Industries Ltd.’s FY21 Annual Report highlights its intention to build multiple growth engines and take PI Industries to the next level in the global arena, with more substantive participation in the life sciences domain. Here are the key insights:
Custom synthesis and manufacturing saw strong growth of 35% YoY (to Rs 33.2 billion) in FY21, driven by volume growth in existing products and the commercialisation of five molecules.
FY21 saw strong growth despite 31% growth in the previous year. The order book position for the year stood at ~$1.5 billion.
the company operationalised two manufacturing facilities (with capacity enhancements of ~15% in key products) and commissioned a pharma lab in Rajasthan in FY21.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.